Stelios Papadopoulos, Ph.D.
Dr. Stelios Papadopoulos is a co-founder and Chairman of the Board of Exelixis, Inc., and a member of the Board of Directors of Biogen Idec, Inc., BG Medicine, Inc., Regulus Therapeutics, Inc. and Joule Unlimited, Inc. He is also a co-founder and was member of the Board of both, Anadys Pharmaceuticals, Inc. (acquired by Hoffman – La Roche in 2011) and Cellzome, Inc. (acquired by GlaxoSmithKline in 2012). In the not-for-profit sector, Dr. Papadopoulos is a co-founder and Chairman of Fondation Santé and a member of the Board of Visitors of Duke Medicine.
Dr. Papadopoulos retired as Vice Chairman of Cowen & Co., LLC in August 2006 after six years with the firm where as an investment banker he focused on the biotech and pharma sectors. Prior to joining Cowen, he spent 13 years as an investment banker at PaineWebber, Incorporated where he was most recently Chairman of PaineWebber Development Corp., a PaineWebber subsidiary focusing on biotechnology. He joined PaineWebber in April 1987 from Drexel Burnham Lambert where he was a Vice President in the Equity Research Department covering the biotechnology industry. Prior to Drexel, he was a biotechnology analyst at Donaldson, Lufkin & Jenrette.
Before coming to Wall Street, Dr. Papadopoulos was on the faculty of the Department of Cell Biology at New York University Medical Center. He continues his affiliation with NYU Medical Center as an Adjunct Associate Professor of Cell Biology. Dr. Papadopoulos holds an M.S. in physics, a Ph.D. in biophysics and an M.B.A. in finance, all from New York University.
Partner, Dechert LLP
Graham Defries advises clients from a range of industry sectors on private equity investments/exits, M&A, corporate finance and collaboration/licensing transactions. He has a particular interest in transactions in healthcare and life science sectors.
Mr. Defries is recommended in Chambers UK 2013, which describes him as “an M&A lawyer first and foremost” who has “a great deal of experience within the life sciences industry and a strong focus on licensing agreements and collaborations.” He is mentioned in Legal 500 UK 2012 for his work advising companies in the pharmaceuticals and biotechnology sector, and is recommended for life sciences work in Chambers UK 2012, where he is described as “a highly skilled cross-border M&A lawyer with an increasingly active profile in the life sciences sector. Clients say he is smart, business-savvy and a top negotiator.”
Mr. Defries is on the London Advisory Board of Maggie’s Centres, a UK charity which builds and runs centres which offers psychological and emotional support, as well as practical advice, to cancer sufferers.
Kevin Johnson, Ph.D.
Partner, Index Ventures
Kevin Johnson is a Partner at Index Ventures working out of the London office.
Prior to joining Index, he was CEO of PanGenetics, an antibody development company based in the Netherlands, and one of the Index Ventures portfolio. Kevin was one of the team at Cambridge Antibody Technology (CAT), heading up research from 1994 onwards. In 1997 he was appointed to the Board, where he held the posts of Research Director and Chief Technology Officer.
Kevin led both the development of CAT's platform technologies, and also their application to the discovery of a number of human antibodies currently in clinical development. Two of these are now marketed, Humira (Abbott Pharmaceutical) and Benlysta (HGS, GSK). He was also part of the management team that floated CAT on the London Stock Exchange (main market).
Kevin graduated in Molecular Biology from Edinburgh University and has a PhD in Pathology from Cambridge University.
Co-founder at Flow Microfluidics / PhD Student at Imperial College London
Ben is a third year PhD student at Imperial College London working in the area of biomaterials. He started Flow Microfluidics (www.flowmicrofluidics.com) with his co-founder Thomas Gibb to provide custom design and fabrication services of microfluidics to life scientists. Ben also helps run the Imperial Create Lab (www.imperialcreatelab.com) which is an initiative created to support students in entrepreneurship all the way from ideation through to scaling at Imperial College London.
Partner, Confluence Tax
Colin is a partner at Confluence Tax LLP and an expert in tax and related commercial issues for early stage technology and life science companies. This includes work on R&D tax credits, fundraising (including EIS and VCT reliefs), share schemes, spin-outs, reorganisations and M&A.
In September 2010, Colin left Deloitte in order to establish Confluence Tax as a firm specialising in providing high quality and cost effective tax advice to SME technology and life science companies.
Colin has worked on tax initiatives with HM Treasury, HMRC and the Office for Life Sciences on R&D tax credits, the patent box and academic spin-outs.
Colin is also a member of the Finance and Tax Advisory Committee of the BioIndustry Association and is a regular speaker on current and future issues relevant to the SME life science sector
Karen Bernstein, Ph.D.
Co-Founder & Chairman, Biocentury
Karen has been writing and publishing on biotechnology since 1987. She holds a Ph.D. in political science from Stanford University and a B.A. in politics and history from Brandeis University, where she now is a member of the Brandeis University Science Advisory Council. She also is on the board of trustees of the Keck Graduate Institute of the Applied Life Sciences. In 2005, the annual gathering of biotechnology chief executive officers at The Biotech Meeting in Laguna Niguel, Calif., inducted Karen into their Hall of Fame, citing her lifetime contribution to the biotech community.
In 2007, Karen received a Special Recognition award at the American Liver Foundation's Salute to Excellence, honoring individuals who have made an outstanding contribution to biotechnology and medical innovation. In 2013, Karen was named one of Silicon Valley Business Journal's 100 most influential women.